Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) EBITDA (2016 - 2025)

Historic EBITDA for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Q3 2025 value amounting to -$2.0 million.

  • Cumberland Pharmaceuticals' EBITDA fell 1598.34% to -$2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.3 million, marking a year-over-year increase of 6970.34%. This contributed to the annual value of -$6.4 million for FY2024, which is 3267.78% up from last year.
  • Latest data reveals that Cumberland Pharmaceuticals reported EBITDA of -$2.0 million as of Q3 2025, which was down 1598.34% from -$747478.0 recorded in Q2 2025.
  • Cumberland Pharmaceuticals' EBITDA's 5-year high stood at $1.3 million during Q1 2025, with a 5-year trough of -$6.2 million in Q4 2023.
  • Over the past 5 years, Cumberland Pharmaceuticals' median EBITDA value was -$1.6 million (recorded in 2021), while the average stood at -$1.6 million.
  • In the last 5 years, Cumberland Pharmaceuticals' EBITDA plummeted by 459139.51% in 2024 and then surged by 16911.58% in 2025.
  • Cumberland Pharmaceuticals' EBITDA (Quarter) stood at -$4.4 million in 2021, then surged by 47.68% to -$2.3 million in 2022, then tumbled by 171.28% to -$6.2 million in 2023, then soared by 70.19% to -$1.8 million in 2024, then decreased by 6.69% to -$2.0 million in 2025.
  • Its last three reported values are -$2.0 million in Q3 2025, -$747478.0 for Q2 2025, and $1.3 million during Q1 2025.